Molecular Weight(MW): 368.29
Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.
1 Customer Review
Purity & Quality Control
Choose Selective IL Receptor Inhibitors
|Description||Diacerein is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.|
Diacerein significantly inhibits LPS-induced IL-1beta production by synovial tissue and cartilage. Diacerein (1 μM) has a significantly less inhibitory effect on cartilage synthesis than culture media containing LPS only. Diacerein (1 μM) decreases NO release in synovial tissue and cartilage media and increases IL-1ra levels in cartilage culture media.  Diacerein (10 μM) enhances the expression of TGF-beta1 and TGF-beta2 in cultured bovine articular chondrocytes.  Diacerein reduces, in a dose-dependent manner, the interleukin-1-beta (IL-1beta)-induced MMP-13 production in osteoarthritic subchondral bone. Diacerein significantly reduces the activity of MMP-13 and cathepsin K in osteoclasts. Diacerein effectively blocks the IL-1beta effect on the osteoclast differentiation process and the survival of mature osteoclasts. 
|In vivo||Diacerein (100 mg/kg/day) significantly suppresses the paw edema and the increase in serum mucoprotein in the adjuvant-induced arthritic rats. Diacerein (30 mg/kg/day) combined with Naproxen (3 mg/kg/day) results in significantly greater anti-inflammatory activity than with naproxen alone in the adjuvant-induced arthritic rats. Diacerein (100 mg/kg/day) also significantly prevents bone loss and reduces the serum alkaline phosphatase and decreases the excretion of urinary hydroxyproline in the ovariectomized rats.  Diacerein (25 mg/kg) decreases the thickness of cartilage and subchondral bone in the lesion (middle) zone of the lateral tibial plateau in Merino wethers. |
-  Yaron M, et al. Osteoarthritis Cartilage, 1999, 7(3), 272-280.
-  Felisaz N, et al. Osteoarthritis Cartilage, 1999, 7(3), 255-264.
-  Boileau C, et al. Arthritis Res Ther, 2008, 10(3), R71.
|In vitro||DMSO||48 mg/mL (130.33 mM)|
|In vivo||Add solvents individually and in order:
1% CMC Na
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02688400||Recruiting||Osteoarthritis|Osteoarthritis, Knee||TRB Chemedica International SA|ArthroLab Inc.||May 2016||Phase 3|
|NCT02242149||Recruiting||Type 2 Diabetes.|Non-alcoholic Fatty Liver Disease||Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ)||September 2014||Phase 3|
|NCT01906801||Completed||Osteoarthritis|Glucosamine|Diacerein||Ramathibodi Hospital||July 2013||Phase 4|
|NCT02177643||Recruiting||Diabetes-Related Complications|Diabetes Mellitus, Type 2|Insulin Resistance||University of Campinas, Brazil|Conselho Nacional de Desenvolvimento Científico e Tecnológico|ANS Pharma||January 2013||Phase 2|
|NCT02060552||Completed||Primary Gout||Tongji Hospital||January 2013||Phase 4|
|NCT01264211||Completed||Rheumatoid Arthritis||TRB Chemedica||October 2010||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.